HIT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Health In Tech Inc (HIT) is not a strong buy right now for a beginner long-term investor, especially one who is impatient and wants to act now. The stock has some encouraging growth in revenue and a recent Buy initiation from Craig-Hallum, but the current price action is weak, options sentiment is unavailable, and proprietary signals do not show a buy setup today. My direct view: hold and wait for a clearer technical turn or a better entry.
HIT is trading pre-market at 1.51, below the pivot level of 1.566, which suggests the stock is currently under mild pressure. MACD histogram is negative and still expanding downward, which confirms bearish momentum. RSI_6 at 40.09 is neutral-to-weak, not oversold enough to signal a compelling rebound. Moving averages are converging, which often means the stock is at a decision point, but there is no confirmed upside breakout yet. Key support is at 1.417 and then 1.325, while resistance sits at 1.715 and 1.807. The nearby chart trend is mixed to weak, not ideal for an immediate long-term entry.
Recent analyst support is positive, with Craig-Hallum initiating coverage at Buy and a $4 target, citing AI/data-driven disruption in the self-funded insurance market, rapid bindable stop-loss quoting, expansion into the large employer market, and a new three-year rate lock product. Financially, Q4 2025 revenue grew 53.09% YoY, showing strong top-line momentum.
There was no news in the past week, so there is no fresh event-driven catalyst. MACD is negative and worsening, suggesting weak near-term price momentum. Gross margin fell sharply to 54.99% YoY, which is a notable quality concern even though revenue is growing. Insider and hedge fund trading trends are neutral, and there is no recent congress trading data. AI Stock Picker has no signal today and SwingMax has no recent signal.
In 2025/Q4, Health In Tech posted revenue of 7,508,585, up 53.09% YoY, which is a strong growth rate. However, net income remained negative at -302,557, and gross margin declined to 54.99% from the prior year, showing profitability pressure despite growth. EPS was -0.01, so the latest quarter shows sales expansion but not yet durable earnings power.
Analyst sentiment is moderately positive. Craig-Hallum initiated coverage on 2026-04-20 with a Buy rating and $4 price target, calling HIT a big idea stock with significant growth potential. Earlier, Maxim kept a Buy rating but lowered the target to $4 from $4.50 on 2026-03-26, citing Q4 results and dilution from an equity raise. Overall, Wall Street pros are bullish on the story and business model, but they are also factoring in dilution and weaker margin quality.
